MATWIN 2014 NOT CONFIDENTIAL Letter of Intent

NOT CONFIDENTIAL

Research project title / Cancerôpole partner
Please type your title here
Project acronym / Reception date (official use)
Please type your acronym here
Key words / File number (official use)
Please type key words here
Project coordinator
Title (i.e.: PhD, MD, Pr…)
First Name
Last Name
Position
Administrative authority or
Name company
Address
E-mail
Phone (direct line) / mobile / +33 / +33 6
Patent Office details and/or Technology Transfer Office details
Name office
Contact name
Address
E-mail
Phone (direct line) / mobile / +33 / +33 6
Budget & duration of the Project
Budget (k€, ATI): / Duration (months)
Deadline and contact details
The Project Application Form must be returned at the latest before Mayr 16th 2014 both to :
1) MATWIN Platform by e-mail a pdf format
2) Your Cancéropôle by e-mail a pdf format and by mail the original copy
MATWIN et Cancéropôle IDF – Cécile FAURIE
Institut Bergonié, 229 cours de l’Argonne; 33076 Bordeaux cedex
: - ': 06 84 01 61 70
Cancéropôle CLARA – Arnaud CUTIVET / Cancéropôle GE – Marc GUENNEUGUES
Bâtiment Domilyon
321 avenue Jean Jaurès; 69007 Lyon
:
': 04 37 90 17 14 / Hôpital de Hautepierre
1av. Molière; 67098 Strasbourg
:
': 03 88 12 75 43
Cancéropôle GO – Jean-Luc CAILLOT / Cancéropôle GSO – Karine MARENDZIAK
Maison de la Recherche en Santé
63, quai Magellan ; 44000 Nantes
:
': 02 53 48 28 75 / Hôpital La Grave, Place Lange
TSA 60033; 31059 Toulouse cedex 9
:
': 06 82 76 75 07
Cancéropôle NO – Véronique PANCRE / Cancéropôle PACA – Clara DUCORD
6 rue du Pr Laguesse
CS 50027; 59045 Lille cedex
:
': 03 20 74 35 83 / Faculté de Médecine - Timone
27 bld Jean Moulin; 13005 Marseille
:
': 04 91 32 47 02
MATWIN timetable
Call for projects / 2014 March 31st
Expression of interest - Deadline “Letter of Intent“ / 2014 May 16th
Notification of acceptance for “Letter of Intent” / 2014 June
Deadline for submission of “Project Application Form” / 2014 September 12th
Multidisciplinary analysis of projects / 2014 Sept to Nov
Letter to selected or unselected applicants / From 2014 December
Coaching session: Review of research plan and training / 2015 January to April
Presentation to the MATWIN International Board / 2015 May
Some questions to think about before to complete a MATWIN Form1

A clear and precise project
§  You must be able to describe your project in two sentences.
An original and innovative project à did you estimate?
§  In what your project is original in relation to the existent?
§  What differentiates your project from the national and international competition
§  What results and knowledge must be protected (PI) or acquired (licence) before the beginning of plan?
A vision of the market with concrete outcomesà did you estimate?
§  The size of the potential worldwide market resulting from the project?
§  What is the aimed segment thanks to your technology, product or service?
§  What are the benefits for users (patient, prescriber, payer, medical insurance)?
§  The essential tools to address this market share (positioning)?
A consistent development plan à did you define?
§  A provisional budget for the duration of the project?
§  The necessary chaining tasks for the realization of the project plan (who makes what, milestones, go/no go)?
§  The way of creating value on the project (exclusive licence, internal development, product’s time-to-market)?
An appropriate organization for shared results à did you define?
§  A skill-based network of professional partners
§  Each project’s partner must be able to benefit from results and value-creation (to be specified in the consortium agreement)?
§  The management to assure a good quality
1] Questions extracted from “Petit guide des questions à poser avant de se lancer dans un projet collaboratif innovant“ Eurobiomedàhttp://www.eurobiomed.org/fileadmin/mes_documents/agenda/documents/petit_guide_des_questions.pdf
Executive summary (1 page max)
WARNING: This executive summary must present briefly your project, in one page max.
Title
à
Application domain (indication & use)
à
Target Population
à
Innovative component
à
Objectives
à
Target Profile
à
Abstract – application domain, objectives, expected outcomes (400 words max)
à
Résumé – domaine d’application, objectifs, résultats attendus (500 mots max)
à
Identified academic and/or industrial partners[1]
Partner / Name / Position / Organism / Laboratory / City / Partner expertise
I.
II.

Breakdown of the approximate budget and other funding sources (% of the total budget)
Staff costs / %
Running expenses / %
Subcontracting internal & external[2] / %
Equipment costs / %
Other funding sources (ANR, INCa ...) / Amount in K€ (ATI) / Obtained / Expected / Date
¨ / ¨
¨ / ¨
… / ¨ / ¨
International classification of your project: NCI-TRWG Developmental Pathway(s)
Assessment modalities: characterize the cancer-related health status of an individual
A.  / I.  Biospecimen-based assessment devices (protocols, reagents, instruments) / ¨
II.  Image-based assessment (agents or techniques) / ¨
Interventive modalities: change the cancer-related health status of an individual, (prevention, treatment)
B.  / I.  Immune response modifiers (vaccines, cytokines, cellular therapy, etc) / ¨
II.  Interventive devices (surgery, radiation) / ¨
III.  Lifestyle alterations (diet, behavioural mechanisms, etc) / ¨
IV.  Agents (drug or biologics including stem cells, epigenetic targets, gene expression) / ¨
Project description and expected outcomes (4 pages max.)
You are requested to present your project research plan from an industrial perspective. Your presentation should not exceed 4 pages and should be structured as follow:
I.  Scientific background: state of the art, rationale, supporting references of relevance to the project.
II.  Innovative components and unmet medical needs: relevance to cancer, potential applications (prognosis, diagnosis, treatment…)
III.  End products/devices: what it will be delivered to patients and healthcare professionals, if possible the anticipated benefits for patients and healthcare professionals and its competitive positioning
IV.  Project Main Objective:
V.  Work plan: list the key steps to reach the objective and for each step briefly describe the experimental design and main deliverables (do not forget this present letter is not confidential)
à
SWOT analysis
A SWOT analysis is a strategic planning method used to evaluate the Strengths, Weaknesses, Opportunities, and Threats involved in a project. It involves specifying the objective(s) of the project and identifying the key internal (S, W) and external (O, T) factors that are favourable and unfavourable to achieving that objective. External factors can be existing or upcoming competitors, regulatory or ethical issues, technology acceptance by professionals/patients …
Strengths / Weaknesses
à / à
Opportunities / Threats
à / à
Intellectual property: Patents, Commercial Interests
Please complete a table for each patent you already filed or that you are planning to file
Patent n° 1
Invention title
Field of application
Inventors
Patent co-owners
IP status
Invention disclosure / date of disclosure
Patent filing / date of filling or expected date of filing
Patent Cooperation Treaty / PCT number
Awarded patent / patent number / awarded countries:
Publications of the partners related to the project during the last 5 years (10 max).
à
Scientific, clinicians or industrials experts
Proposed for review of the project without conflict of interest with the partnersLat least 3 or 4 experts)
I.  Name, organism, city, e-mail
.....
Undesirable because of conflict of interest
I.  Name, organism, city, e-mail
.....
Project coordinator signature
I, undertaking (name) ………………………………………………………
I.  authorise the MATWIN society to share all information regarding my Letter of Intent for evaluation purposes, under the condition that each person who accesses this information is bound by a confidentiality agreement,
II.  have obtained the agreement of all associated partners for their participation in this research project,
III.  am aware the present letter of intent will be disclosed to third partiers and therefore does not contain confidential information.
And for project leader from private society (start-up, spin-off, micro-enterprise) ONLY
IV.  certify that my company incorporated under French law, was recently created (less than 3 years). The staff is smaller than 10 FTE and the turnover is low or non-existent as the equity capital made up of small amounts. Be careful : certifying documents are required
Date of the creation of company / SIRET n°
Number of employees / FTE
Turnover of the past financial year
Equity capital
Date: Signature:

Not Confidential – Apr. 2014 Page 7 on 7

[1] Our recommendation is to limit number of associated partners to 3 to 5 teams, including yours.

[2] This amount cannot be more than 30% of the Matwin requested budget without Matwin authorisation